BeyondSpring Inc Stock News

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring (BYSI), with a price target of $41.00. The

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Beyondspring (BYSI – Research Report),

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that t

Charles Schwab Investment Management Inc. boosted its position in shares of Beyondspring Inc (NASDAQ:BYSI) by 8.6% during the fourth quarter, Holdings Channel reports. The firm owned 27,305 shares of

William Blair reiterated their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a research note issued to investors on Thursday, AnalystRatings.com reports. Several other research analysts also r

Alyeska Investment Group L.P. acquired a new position in shares of Beyondspring Inc (NASDAQ:BYSI) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission.

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyondspring (BYSI) and Portola Pharma (PTLA) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyondspring ( BYSI – Research Report ) and Portola Pharma ( PTLA – Research Report ) with bullish

Barclays PLC increased its holdings in Beyondspring Inc (NASDAQ:BYSI) by 67.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. T

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the su

Beyondspring Inc (NASDAQ:BYSI) saw a significant decline in short interest in the month of February. As of February 14th, there was short interest totalling 669,000 shares, a decline of 5.2% from the

Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN), Beyondspring (BYSI) and Agenus (AGEN).

Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN – Research

No matter which strategy is employed or what types of stocks to buy are sought after, investors want to see returns.

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that n